The results showed PBMT increased the number of CD4+ IFN-γ+ T cells in the brain tissue (APP/PS1 + PBMT: 0.26%; APP/PS1: 0.14%; 3xTg-AD + PBMT: 0.42%; 3xTg-AD: 0.06%), versus no treatment controls (Fig. 4A, B), and the number of CD4+ IL-10+ T cells in the brain tissue were also increased by PBMT (APP/PS1 + PBMT: 0.14%; APP/PS1: 0.06%; 3xTg-AD + PBMT: 0.08%; 3xTg-AD: 0.03%), compared with untreated groups (Fig. 4A, B). The gene discussed is CD4; the disease is Alzheimer disease.